We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 149.12 | 263 | 10:35:18 |
By Dominic Chopping
A committee appointed by the Norwegian government said Monday that the country should exclude the AstraZeneca and Johnson & Johnson vaccines from its immunisation program.
The committee--which is made of a panel of doctors, professors and researchers from Norway, France and the U.K.--said the vaccines shouldn't be used due to risk of rare but serious side-effects.
However, it said they should be made available outside of the country's official vaccination programme to anyone who wants to take them on a voluntary basis.
"The government will now thoroughly review the report and use it as a basis for decisions together with the National Institute of Public Health's recommendation," Health Minister Bent Hoie said in a statement.
Last month, the National Institute of Public Health recommended that AstraZeneca's vaccine be removed from the immunisation programme completely, but the government wanted a further assessment and set up the expert panel to look into both vaccines in more detail before making a decision.
Use of the AstraZeneca vaccine in the country has been paused since March 11, after reports of blood clots in people who had received the jab.
The institute said Monday that it recommended not using the Johnson & Johnson vaccine for anything other than to build up an emergency stockpile, for use in the event of a failure in deliveries of other vaccines.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
May 10, 2021 07:07 ET (11:07 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions